laborant / Shutterstock.com
13 February 2019Americas
Boehringer Ingelheim teams up with IBM to explore blockchain
The Canadian units of IBM and pharmaceutical company Boehringer Ingelheim have united to explore the use of blockchain technology in clinical trials.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
14 November 2018 Technology company IBM is seeking to patent the use of blockchain in open scientific research, including experiments, data collection, and analysis.
Big Pharma
30 May 2019 German pharmaceutical company Boehringer Ingelheim has entered into a second licence and collaboration agreement with Danish biotech company Gubra for the development of an obesity treatment.
Americas
17 June 2019 The US Food and Drug Administration has chosen Merck & Co, IBM, KPMG, and Walmart to form a pilot project aimed at evaluating the use of blockchain to protect pharmaceutical product integrity.
Editor's picks
Editor's picks
Americas
14 November 2018 Technology company IBM is seeking to patent the use of blockchain in open scientific research, including experiments, data collection, and analysis.
Big Pharma
30 May 2019 German pharmaceutical company Boehringer Ingelheim has entered into a second licence and collaboration agreement with Danish biotech company Gubra for the development of an obesity treatment.
Americas
17 June 2019 The US Food and Drug Administration has chosen Merck & Co, IBM, KPMG, and Walmart to form a pilot project aimed at evaluating the use of blockchain to protect pharmaceutical product integrity.
Americas
14 November 2018 Technology company IBM is seeking to patent the use of blockchain in open scientific research, including experiments, data collection, and analysis.
Big Pharma
30 May 2019 German pharmaceutical company Boehringer Ingelheim has entered into a second licence and collaboration agreement with Danish biotech company Gubra for the development of an obesity treatment.
Americas
17 June 2019 The US Food and Drug Administration has chosen Merck & Co, IBM, KPMG, and Walmart to form a pilot project aimed at evaluating the use of blockchain to protect pharmaceutical product integrity.